aprott/iStock via Getty Images Eli Lilly has filed lawsuits against three companies for continuing to sell compounded versions of tirzepatide, the active ingredient in its weight loss and type 2 diabetes meds Zepbound and Mounjaro. Compounded versions of drugs that still have patent protection.